Condition: RSV Infection · Sponsor: Clover Biopharmaceuticals USA, LLC
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
This description comes directly from the study's public registry record.
Xuesong Pei, MD · (+86) 18515445890 · xuesong.pei@cloverbiopharma.com
Always discuss trial participation with your own doctor first.
| AMR Phoenix | Phoenix, Arizona, United States | Recruiting |
| AMR Fort Myers | Fort Myers, Florida, United States | Recruiting |
| AMR Lexington | Lexington, Kentucky, United States | Recruiting |
| AMR Kansas City | Kansas City, Missouri, United States | Recruiting |
| Knoxville | Knoxville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06843317